SalesTrax.com Research: Merck & Company

Articles found below have been submitted through various PR and news sources and don’t necessary reflect the views of SalesTrax or its employees.


Pharmaceutical Business Review

2009-09-18 12:04
Wellcome Trust, Merck To Develop Affordable Vaccines For Low-Income Countries
Joint venture will be based in India

2009-09-18 12:04
Dey Settles State Of Utah Pricing Litigation
Merck to pay full amount of the settlement and all costs and other expenses associated with Medicaid reimbursement lawsuits involving Dey

2009-09-18 12:04
Sanofi-Aventis Completes Acquisition Of Merck's Interest In Merial
Acquisition is expected to be accretive to sanofi-aventis' adjusted net income from the first year

2009-09-16 04:03
Merck Provides New Data From Phase IIB Clinical Study Of Odanacatib
Odanacatib, a cathepsin inhibitor which selectively inhibits the cathepsin enzyme

2009-09-15 12:05
Merck Evaluates Isentress In comparison To Efavirenz
Study evaluated combination therapy through 96 weeks in HIV-1 treatment-naive patients

2009-09-15 04:04
Merck Reports New Data From CLARITY Phase III Trial For Cladribine Tablets
Cladribine Tablets, to treat patients with relapsing-remitting multiple sclerosis

2009-09-15 04:04
Merck Reports Results Of 40-Week IMPROVE Study
Study showed MRI benefits of Rebif, seen early in relapsing-remitting multiple sclerosis treatment and sustained over time

2009-09-11 12:04
Merck Provides Update On Its Investigational CGRP Receptor Antagonists
Telcagepant (MK-0974) and MK-3207, for the intermittent treatment of acute migraine

2009-09-09 12:04
Merck Acquires Suzhou Taizhu Technology Development Co.
Merck has also acquired the production site of Taizhu in Taicang

2009-09-09 12:04
Merck Opens New Cosmetic Technology Center In Darmstadt
CTC offers ultra-modern technology, spacious laboratories and optimally equipped rooms for seminars and meetings

2009-09-04 12:04
Merck Sharp & Dohme Launches SAFLUTAN In International Market
Company launched SAFLUTAN in UK and Spain

2009-08-20 12:03
Merck Wins Singulair Patent Infringement Lawsuit Against Teva
Court blocks the approval of Teva's generic versions until the expiration of the patent

2009-08-10 04:02
Merck Shareholders Approve Merger With Schering-Plough
99% of the company?s outstanding shares voted in favor of the transaction

2009-08-06 04:03
Merck, Schering-Plough Seal Agreement To Resolve Lawsuits
Settlement would resolve all class action lawsuits that seek economic damages related to the purchase of Vytorin and Zetia

2009-08-03 04:03
Merck Presents Data For Combination Of Erbitux With Standard First-Line Therapy In NSCLC
Showed efficacy in progression-free survival and overall survival

2009-07-31 12:03
Merck Serono Partners MSM
To establish drug discovery collaboration targeted to complex cell surface receptors

2009-07-31 12:03
Merck Targets 20% Reduction In Carbon Dioxide Emissions
To expand measurement scope from direct emissions to indirect emissions

2009-07-31 12:03
Merck Requests Re-examination Of CHMP Opinion For Erbitux
Company would work closely with CHMP to unravel the value of Erbitux for patients benefit

2009-07-31 08:03
Sanofi-aventis To Acquire Merck's Interest In Merial
Acquisition values Merial on the basis of 3.0 x 2008 sales and 10.2 x 2008 earnings before interest and taxes

2009-07-29 04:03
Cardiome Receives Milestone Payment From Merck
In connection with the collaboration and license agreement for the development and commercialization of vernakalant

2009-07-27 12:03
Merck Receives Positive Opinion From CHMP Recommending Expanded Marketing Authorisation For ISENTRESS
To be reviewed by the European Commission

2009-07-27 04:03
Merck Proposes Settlement Of Litigation With Schering-Plough
Proposed settlement is not in any way an admission of any wrongdoing or liability in connection with plaintiffs' allegations, said Merck

2009-07-24 12:03
Merck Posts Steady Revenues At E1902M
Despite of economic crisis, company expects to meet group guidance for 2009

2009-07-23 12:04
Merck Submits MAA For Cladribine Tablets In Europe
An investigational oral formulation of cladribine, for patients with relapsing-remitting multiple sclerosis

2009-07-22 08:02
Merck Posts Q2 2009 Financial Results
Company's net income for the second quarter was $1556.3m

2009-07-17 16:04
Biowa Signs License Agreement With Merck
For the research, development and commercialization of their antibody therapies with enhanced antibody-dependent cellular cytotoxicity (ADCC)

2009-07-17 04:03
Japanese Ministry of Health Approves Merck?s Gonal-f
Gonal-f is intended to be used for ovulation induction in infertile women

2009-07-16 12:04
Merck, Schering-Plough Resolve Investigation Under State Consumer Protection Statutes
Companies agreed to reimburse the investigative costs which totaled $5.4 million

2009-07-10 04:03
Merck & Co, Portola Sign Worldwide License Agreement
Merck and Portola to co-promote betrixaban in the US

2009-06-25 04:03
Actavis Launches Finasteride As Patent Expires In France
Finasteride, used for the treatment of prostate cancer, is generic equivalent of Merck?s Proscar

2009-06-23 04:03
Merck KGaA Initiates Phase-III Study Of Stimuvax
Stimuvax to treat patients with advanced, inoperable breast cancer

2009-06-15 12:03
Merck? Declaration In Response To FDA's Update On Singulair
Singulair, supported by data from controlled clinical trials in more than 20,000 patients

2009-06-15 04:04
ImClone, Bristol-Myers Squibb Sign Agreement With Merck
For co-development and co-commercialization of Erbitux in Japan

2009-06-12 12:04
Xenon Signs Collaboration Agreement With Merck
Merck to exclusively license targets and compounds from Xenon for development and commercialization

2009-06-12 12:04
Merck Terminates Research Collaboration, License Agreement
Entered the collaboration with Neuromed in March, 2006

2009-06-11 12:04
Metabasis, Merck To Advance AMPK Activator For Late Preclinical Development
Metabasis to receive one time payment of $6 million

2009-06-09 12:04
Initial Therapy With Merck' JANUMET To Provide Greater Blood Sugar Lowering
Data pooled from 104 weeks of studies showed sustained results for over two years

2009-06-08 04:03
Merck' Rolofylline Fails Efficacy Trial For Acute Heart Failure
Merck will continue to analyze the data with outside experts

2009-06-02 12:03
AstraZeneca, Merck Collaborate To Investigate Novel Combination Anticancer Regimen
AstraZeneca and Merck have entered into an agreement to research a novel combination anticancer regimen composed of two investigational compounds, MK-2206 from Merck and AZD6244 from AstraZeneca.


Forbes.com

2009-11-26 16:00
Zetia's Miraculous Popularity
How did Merck persuade patients to spend $21 billion on a cholesterol fighter that may not prevent heart attacks?

2009-11-18 08:00
Answering The Vytorin Question
Merck scores a PR win at a cardiology conference, but that doesn't mean its cholesterol drugs are effective.

2009-11-15 20:00
Another Vytorin Mess For Merck
A new study, though flawed, inflicts more damage on the company's Zetia and Vytorin cholesterol pills.

2009-11-13 08:00
Layoffs Sting Big Pharma
Merger-related cuts at Merck and Pfizer show how the mighty drug industry has fallen.

2009-08-31 20:02
Merck's Top Brass Stays Put
There are a lot of musical chairs involved in the company's merger with Schering, but big names aren't playing.

2009-08-07 08:02
Merck's AIDS Triumph
It went where other drug companies feared to tread and got a big-selling HIV drug.

2009-07-09 20:02
Another Downer For Merck's Cholesterol Drugs
Why investors are right to worry that a new study could damage the company's outlook.

2009-06-05 16:04
Merck's Heart Failure Failure
One of the drug industry's most renowned names is having a lot of trouble landing new drugs.